Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers

• Status: Completed
• Trial end date: 2019-08-05
• Target enrollment: 0
• Participant gender: Male

Summary

Proton pump inhibitors (PPIs) are treatment of choice for different gastrointestinal disorders common in type 2 diabetes. Sulfonylureas (SUs) are anti-diabetes agents particularly widely used in developing countries. Gliclazide, a recommended SU drug, is metabolised in part by CYP2C19, the main enzyme responsible for the PPI metabolism.

A randomised, placebo-controlled, two-sequence, two-period crossover study will be performed to explore whether gliclazide pharmacokinetics (PK) and pharmacodynamics (PD) are altered upon co-administration with omeprazole. Sixteen healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers (EM/UM), will receive placebo or omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. Plasma concentration of gliclazide will be measured for 24 hours, and plasma glucose and insulin levels up to 12 hours after gliclazide administration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Sarajevo
• Collaborators: General Hospital Prim. Dr. Abdulah Nakas; University of Dundee; Wellcome Trust
• Treatments: Gliclazide; Omeprazole

Criteria

Inclusion Criteria:

• Men

• Age 18-30 years

• Non-smokers

• CYP2C19 extensive/ultrarapid metabolisers

Exclusion Criteria:

• medical history of hepatic, renal, gastrointestinal and hematologic disease or any acute or chronic disease, or drug allergy to sulfonylureas or PPIs or history of drug abuse

• abnormalities in physical examination, ECG and routine clinical laboratory tests (including fasting blood glucose concentration)

• medication use during the 14 days prior and during the study period

• grapefruit, grapefruit juice, alcohol, beverages or food containing methylxanthines use during 72 h prior and during the study period